Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.43 |
| ▸ | PYGL | P06737 | 3/20 | 0.43 |
| ▸ | PYGM | P11217 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172797 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL12581436 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL1199053 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3223069 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL16812689 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL24720641 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3219087 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL17354424 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL3219097 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 | |
| SCHEMBL12422622 | 1.00 | PYGB (0.43) | PYGBPYGLPYGMLMNAGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3142661-B1 | METHOD FOR SUPPRESSING GLUCAGON SECRETION OF AN SGLT2 INHIBITOR | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-08-05 | — | — | US | disclosed |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-25 | — | — | US | disclosed |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-27 | — | — | US | disclosed |
| US-20200291004-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| US-10759729-B2 | Compounds for treating diabetes | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2020-09-01 | — | — | US | disclosed |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | Je II Pharmaceutical Co., Ltd. (KR) | 2020-08-25 | — | — | US | disclosed |
| EP-3404033-B1 | C-GLUCOSIDE DERIVATIVE CONTAINING FUSED PHENYL RING OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | JEIL PHARMACEUTICAL CO LTD (KR) | 2020-08-05 | — | — | EP | disclosed |
| US-10696662-B2 | 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-30 | — | — | US | disclosed |
| WO-2019215633-A1 | 5,5-DIFLUORO- AND 5-FLUORO-5-METHYL-C-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-14 | — | — | WO | disclosed |
| EP-1679965-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-19 | — | — | EP | disclosed |
| WO-2006058597-A1 | TETRAHYDROPYRANE DERIVATIVES FOR USE AS ANTIDIABETICS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| US-20050032711-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | US | disclosed |
| WO-2005011592-A2 | SUBSTITUTED INDAZOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012243-A2 | SUBSTITUTED INDOLE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012242-A2 | SUBSTITUTED BENZIMIDAZOLE-, BENZTRIAZOLE-, AND BENZIMIDAZOLONE-O-GLUCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012318-A2 | SUBSTITUTED FUSED HETEROCYCLIC C-GLYCOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696662-B2 | 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | PYGB 726/4885PYGL 294/4885PYGM 1032/4885 |
| US-20200291004-A1 | 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS | SLC5A2, SLC5A1, SLC2A2 | PYGB 698/4885PYGL 254/4885PYGM 964/4885 |
| US-20050032711-A1 | Substituted indazole-O-glucosides | GYS2, GPR119, UGGT1 | PYGB 18/4885PYGL 4/4885PYGM 26/4885 |
| US-10759729-B2 | Compounds for treating diabetes | SLC5A2, GPR119, DPP4 | PYGB 1436/4885PYGL 197/4885PYGM 1421/4885 |
| US-20050032712-A1 | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides | GANAB, GCG, GANC | PYGB 115/4885PYGL 28/4885PYGM 111/4885 |
| US-11014917-B2 | 5-fluoro-c-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | PYGB 698/4885PYGL 254/4885PYGM 964/4885 |
| US-10815210-B2 | Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators | SLC5A2, SLC5A1, SLC2A2 | PYGB 606/4885PYGL 323/4885PYGM 590/4885 |
| US-20210238170-A1 | 5,5-Difluoro- and 5-Fluoro-5-Methyl-C-Glycoside Derivatives Useful As Dual SGLT1 / SGLT2 Modulators | SLC5A2, SLC5A1, SLC2A4 | PYGB 343/4885PYGL 76/4885PYGM 301/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | PYGB 4/4885PYGL 2/4885PYGM 19/4885 |
| US-10752604-B2 | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same | SLC5A2, SLC5A1, UGGT1 | PYGB 161/4885PYGL 45/4885PYGM 125/4885 |
| US-20050037980-A1 | Substituted fused heterocyclic C-glycosides | UGCG, UGGT1, GCG | PYGB 191/4885PYGL 11/4885PYGM 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.